INTRODUCTION {#sec1-1}
============

The term "acute coronary syndrome" (ACS) encompasses a range of thrombotic coronary artery diseases, including unstable angina (UA), and both ST -- segment elevation (STEMI) and Non-ST -- segment elevation myocardial infarction (NSTEMI), mostly induced by local coronary thrombosis as an acute complication of atherosclerosis.\[[@ref1]\] Patients with an acute coronary syndrome have a high risk of suffering subsequent cardiac events.\[[@ref2]--[@ref4]\]

Coronary plaque disruption, with consequent platelet aggregation and thrombosis, is the most important mechanism by which atherosclerosis leads to the acute ischemic syndromes of unstable angina, acute myocardial infarction, and sudden death.\[[@ref5]\]

With growing evidence that atherosclerosis is an inflammatory process, several plasma markers of inflammation have been evaluated as potential tools for the prediction of coronary events.\[[@ref6]\] These markers of inflammation include serum amyloid A, interleukin -- 6, homocysteines, fibrinogen levels, fibrinolytic capacity, apolipoprotein -- A, apolipoprotein B-100, lipoprotein (a) and C-reactive protein (CRP).\[[@ref7]\]

Increased concentrations of CRP have been reported in unstable angina\[[@ref8]\] and in acute myocardial infarction.\[[@ref9]\] Liuzzo and associates\[[@ref10]\] have shown that concentrations of CRP and serum amyloid A in unstable angina increase independently of myocardial cell injury. They also reported that higher concentrations of CRP at the time of hospital admission (\>3.0 mg/l) were predictive of a poor outcome in unstable angina.

CRP has been shown to predict risk in a wide variety of clinical settings; it has incremental value in addition to standard lipid screening for primary prevention.\[[@ref11]--[@ref13]\] A recent analysis by Chew *et al*.\[[@ref14]\] shows that CRP predicts the risk of death or myocardial infarction at 30 days among patients undergoing percutaneous coronary intervention. CRP was found to be independently associated with the recurrence of cardiovascular events and with death in the mid to long term.\[[@ref15][@ref16]\] It has been suggested that CRP may not only be a marker of generalized inflammation but directly and actively participates in both atherogenesis\[[@ref17][@ref18]\] and atheromatous plaque disruption.\[[@ref19]\]

The aim of the present study was to evaluate the prognostic value of CRP in predicting cardiovascular outcome in patients presenting with acute coronary syndromes.

PATIENTS AND METHODS {#sec1-2}
====================

This prospective study was conducted by the Department of Pathology in collaboration with the Department of Cardiology, Bolan Medical College Complex, Quetta, Pakistan, between January and December 2009. A total of 963 consecutive patients presenting with chest pain were enrolled in the study. All patients were assessed by a detailed history and physical examination and relevant laboratory investigations to document presence of ACS. Patients who presented with history of typical chest pain and ST elevation or depression of \>0.1 mV in two concordant ECG leads, or clinical picture of unstable angina were included.

The exclusion criteria were acute myocardial infarction within previous month,\[[@ref20]\] inflammatory or neoplastic conditions likely to be associated with an elevated CRP and patients with valvular heart disease, hepatic failure and renal failure.

Patients were divided into four groups. Group-1 included 232 patients with a final diagnosis of unstable angina (men 160; women 72; mean age 53.6 ± 2.8 years); Group-2 included 258 patients with a final diagnosis of acute ST elevation myocardial infarction (men 182; women 76; mean age 54.4 ± 4.7 years); Group-3 included 286 patients with a final diagnosis of acute Non-ST elevation myocardial infarction (men 201; women 85; mean age 52.8 ± 5.2 years) and Group-4 was a control group which included 187 patients (men 112; women 75; mean age 53.7 ± 4.9 years). The control group included patients, who initially presented with chest pain but were found to be non-cardiac in origin on the basis of unremarkable serial ECGs and normal cardiac markers. There was no evidence of any infection, inflammation, malignancy, heart failure or valvular heart disease in these patients.

Venous blood under aseptic conditions was withdrawn from patients at the time of admission. The blood samples were shifted to a tube and clotted at room temperature. The tube was centrifuged for 5 minutes and the serum was separated for CRP, CK, CK-MB and Troponin T.

CK-MB was measured immunochemically (ACS: 180 analyzer: Bayer)\[[@ref21]\] The upper reference limit was 7.5 μg/L and the assay was linear from 0 to 500 μg/L. The Troponin T was measured by ELISA on an ES300 analyzer (Boehring Mannheim)\[[@ref20]\] The upper reference limit was 0.4 μg/L and the assay was linear from 0 to 15 μg/L.

CRP was measured with nephelometric assay (Boehring Diagnostics)\[[@ref22]\] The detection limit was 0.2 mg/L, the assay was linear from 0.2 to 230 mg/L, and the CV was \<3% at a concentration of 2 mg/L. The 95^th^ percentile in 120 healthy donors in our institution was established at 3.0 mg/L.

A 90-day follow-up was arranged by telephonic interview either with the patients or their relatives. All patients were studied prospectively without knowledge of the CRP levels for cardiovascular complications including mortality, (re-) myocardial infarction, recurrent unstable angina or heart failure.

The diagnosis of acute myocardial infarction was established according to the WHO criteria,\[[@ref23]\] with a history of chest pain lasting \>20 minutes, characteristic ECG alterations, and peak CK-MB above 14 μg/L (twice the upper limit of normal or previous elevated value) or positive troponin T (\>0.4 ng/ml). Acute Non-ST elevation myocardial infarction was considered present when peak CK-MB exceeded 14 μg/L and no new Q-waves developed on the electrocardiogram. Unstable angina was defined as with typical chest pain at rest (usually more than 20 minutes), new onset of exertional chest pain with marked limitation of ordinary physical activity, or recent (\<2 months) increase in the severity of angina.\[[@ref5]\] with a peak CK-MB above the upper limit of normal (7.0 μg/L) but below the predefined limit for acute myocardial infarction (as were patients without CK-MB elevation).

Cardiac death was defined as a death due to myocardial infarction, cardiac arrhythmias (sustained ventricular tachycardia, ventricular fibrillation and supraventricular tachycardia with hemodynamic compromise), cardiogenic shock or congestive cardiac failure.

All patients gave written informed consent for participation in the study.

Statistical analysis was done by SPSS version 14.0 in calculating the frequency, percentages and the Chi-square.

RESULTS {#sec1-3}
=======

The baseline characteristics of the patients in different groups are given in \[[Table 1](#T1){ref-type="table"}\]. The values of CRP, CK, CK-MB and Troponin-T in each group are shown in \[[Table 2](#T2){ref-type="table"}\]. The CRP levels were significantly higher in group-2 and group-3 as compared to group-1 and group-4 (*P* \< 0.00001).
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Mean values of various markers in different groups
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CRP levels ranged from 0.5 to 95 mg/ml \[[Figure 1](#F1){ref-type="fig"}\]. The overall mean ± SE was 17.6 ± 7.96 mg/ml (95% CI = 1.66 - 33.6). The distribution of cardiac events among different groups is shown in \[[Table 3](#T3){ref-type="table"}\] while \[[Table 4](#T4){ref-type="table"}\] depicts the incidence of cardiac events according to CRP level in each group.
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Distribution of cardiac events according to CRP levels

![](HV-13-7-g004)

###### 

Significance of difference between occurrences of cardiac events among various groups
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In Group-1, at the time of hospital admission, the CRP levels were \>3.0 mg/L in 64 (28%) patients. The mean±SE was 5.43±0.48 mg/L. In Group-2, the CRP levels were \>3.0 mg/L in 183 (71%) of patients. The mean±SE was 29.4±1.73 mg/L. In Group-3, CRP levels were \>3.0 in 223 (78%) of the patients and mean ± SE was 27.1±1.67 mg/L. In Group 4 (Control Group), the CRP levels at the time of admission were \>3.0 mg/L in 19 (10%) of the patients. The mean±SE was 2.16 0.11 mg/L.

A 90-day follow-up was done in all cases. In Group-1, 35 (15%) patients suffered acute myocardial infarction, 5 (2%) died of a coronary event, 25 (10.8%) had recurrent angina and 20 (12%) developed heart failure in the follow-up. Out of 168 patients with CRP £3 mg/L, 21.4% developed a cardiac event, while the proportion of those developing cardiac event among 64 patients with a CRP \>3 mg/L was much higher (76.6%). The difference was statistically significant (*P* \< 0.0001). In Group-2, 46 (17.8%) suffered another MI, 23 (8.9%) died of a coronary event, 57 (22.1%) suffered angina and 72 (27.9%) developed heart failure in the follow-up. The CRP levels were elevated in 167 (84%) out of these 198 patients. Out of 75 patients, who had CRP £ 41.3% had a cardiac event compared to 84.3% of those, who had CRP \>3 mg/L (*P* \< 0.0001). In Group-3, 55 (19.2%) suffered another MI, 34 (11.9%) died of a coronary event, 77(26.9%) suffered angina and 89 (31.1%) patients developed heart failure. Among those with CRP £3 mg/L, 60.3% patients suffered a cardiac event, while their proportion was 91.2% in those with CRP \>3 mg/L (*P* \< 0.0001). In Group-4, no coronary events were recorded in the follow-up period.

DISCUSSION {#sec1-4}
==========

The present study shows that the acute phase reactant, CRP, is significantly elevated in patients with acute coronary syndromes compared to the control group. The number of patients with CRP elevations was much higher in Group-2 and 3 (71% and 78%) vs Group-1 (28%). The CRP levels were much more significant in Group-2 and 3 compared to Group-1 and 4. The mean CRP levels in Group-2 and 3 were 29.26 and 31.56 as compared to Group-1 and Group-4 where the mean CRP were 9.22 and 3.78, respectively. It was seen from the study that the CRP levels were more elevated in patients with Non-STEMI in comparison to STEMI, signifying a greater degree of inflammation and probably myocardial damage as well.

The present study results are comparable to the studies by Cavusoglu *et al*.\[[@ref24]\] and Tomado *et al*.\[[@ref25]\] who demonstrated that the CRP concentrations in patients presenting with acute coronary syndromes, within 6 hours of onset of symptoms were significantly higher as compared to the Control Group. The inflammatory process has been shown to be one of the mechanisms causing plaque rupture leading to elevated CRP levels in less than 6 hours in patients with acute coronary syndrome\[[@ref21]\] In patients presenting with ACS, hsCRP concentrations are more than 10-fold higher than in patients with stable coronary disease or no known coronary disease.\[[@ref8]\] In prior studies, increased concentrations of hsCRP have been shown to be associated with mortality in patients with UA and NSTEMI.\[[@ref10][@ref14][@ref16][@ref26]\] There are few data regarding hsCRP concentrations and the risk of heart failure in patients with ACS. Several studies found a relationship between increased concentrations of hsCRP and future episodes of heart failure among elderly patients with no known cardiovascular disease,\[[@ref27]\] between hsCRP and heart failure in patients with STEMI,\[[@ref28]\] or an association between hsCRP and heart failure when these variables were used as a part of a composite endpoint in patients with ACS.\[[@ref29][@ref30]\] In the present study, the relationship between even mild increases in baseline CRP was strongly and independently associated with the development of heart failure, suggesting that the intensity of the inflammatory response increases the risk of mechanical consequences and complications of ischemic injury and therefore may play a role in the development of heart failure. Increased concentrations of CRP may then help to identify patients at risk of developing congestive heart failure after ACS and prompt closer surveillance and more aggressive therapy and perhaps novel therapy aimed at prevention of adverse remodeling. Assessment of CRP on admission provides independent prognostic information and thereby improves the ability to identify those patients at highest risk of death and heart failure.\[[@ref31]\]

A study by Mach *et al*. showed that among patients with acute ischemic heart disease and no biological markers of myocardial necrosis, the CRP concentration at the time of admission was significantly higher in patients in whom an acute myocardial infarction was ultimately diagnosed, while in patients with unstable angina the CRP levels were low.\[[@ref31]\]

In the present study, the 90-day follow up shows that the Groups-2 and 3 had greater number of complications compared to Group-1. The mortality was only 2 % in Group-1 compared to 9% and 12% in Groups-2 and 3, respectively. The overall incidence of a major coronary event was 87% in patients with abnormal CRP vs 13% in patients with a normal CRP.

Liuzzo *et al*.\[[@ref10]\] demonstrated that CRP elevation in patients with unstable angina, without evidence of myocardial damage as assessed with troponin T, is associated with poor outcome. In another study, Liuzzo *et al*., showed that severe myocardial ischemia in patients with variant angina without atherosclerotic coronary artery disease does not by itself induce an increase in plasma CRP.\[[@ref32]\] Therefore, it is likely that CRP elevations are due to activation of inflammation. It has been shown that other pro-inflammatory cytokines such as interleukin-6, interleukin-8 and TNF-a are elevated on admission in patients with acute coronary syndromes\[[@ref33]--[@ref35]\] and that these elevations may be associated with a worse outcome.\[[@ref33]\]

It has been shown that CRP stimulates production of tissue factor by mononuclear cells, the main initiator of blood coagulation.\[[@ref36]\] In addition, it has been suggested that CRP together with phospholipase A2 may cause complement activation and promote phagocytosis of damaged cells by activated neutrophils.\[[@ref37]\] Therefore, it is conceivable that an elevated CRP signifies ongoing activation of inflammation that characterizes unstable coronary artery disease and indeed may be one of the causal factors of instability.

CRP levels were higher in patients with acute coronary syndromes as compared to the control group. However, it could not be ruled out that whether the observed difference would reach a significant level if a significantly larger sample size is used.

The study was not designed to study the correlation between CRP elevation and the rise in troponin T levels and their combined and independent effects on the coronary events in the follow-up.

CONCLUSIONS {#sec1-5}
===========

The measurement of CRP at the time of admission in patients with suspected coronary artery disease may be helpful in identifying a group of patients who may be at high risk of cardiac complications and these patients need aggressive cardiac management and close monitoring after discharge.

We are very thankful to Dr N. Rehan for his assistance and support in the statistical analysis of the study. We are grateful to the Department of Cardiology, Bolan Medical College Complex Quetta for their support and help. We would like to thank all the doctors, nurses, paramedical staff and the medical students who were linked, directly or indirectly, with this study for their support and input.

**Source of Support:** Nil

**Conflict of Interest:** None declared.
